249 related articles for article (PubMed ID: 2538331)
1. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 2. Effect of VIP on cAMP production and on cell-surface VIP-binding sites.
Martin JM; Luis J; Marvaldi J; Pichon J; Pic P
Eur J Biochem; 1989 Mar; 180(2):435-9. PubMed ID: 2538331
[TBL] [Abstract][Full Text] [Related]
2. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 1. Molecular characterization of the binding site.
Luis J; Martin JM; el Battari A; Reynier M; Marvaldi J; Pichon J
Eur J Biochem; 1989 Mar; 180(2):429-33. PubMed ID: 2538330
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide receptor regulation of cAMP accumulation and glycogen hydrolysis in the human Ewing's sarcoma cell line WE-68.
Van Valen F; Jürgens H; Winkelmann W; Keck E
Cell Signal; 1989; 1(5):435-46. PubMed ID: 2561912
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the expression of the VIP receptor by serum factors on the human melanoma cell line IGR39.
Bellan C; Fabre C; Secchi J; Marvaldi J; Pichon J; Luis J
Exp Cell Res; 1992 May; 200(1):34-40. PubMed ID: 1314189
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of vasoactive intestinal peptide (VIP) binding on human melanoma cells IGR39 by nitric oxide: cGMP is not involved.
Fouchier F; Pichon J; Forget P
Eur J Cell Biol; 1994 Jun; 64(1):71-7. PubMed ID: 7957315
[TBL] [Abstract][Full Text] [Related]
6. Structural and functional analysis of the human vasoactive intestinal peptide receptor glycosylation. Alteration of receptor function by wheat germ agglutinin.
Chochola J; Fabre C; Bellan C; Luis J; Bourgerie S; Abadie B; Champion S; Marvaldi J; el Battari A
J Biol Chem; 1993 Feb; 268(4):2312-8. PubMed ID: 8381403
[TBL] [Abstract][Full Text] [Related]
7. Modifications of the binding properties of the human VIP receptor of IGR39 cells by sulfhydryl reagents.
Fouchier F; Forget P; Pic P; Marvaldi J; Pichon J
Eur J Cell Biol; 1992 Dec; 59(2):382-8. PubMed ID: 1337321
[TBL] [Abstract][Full Text] [Related]
8. Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell line.
Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM; Cooper CW
Endocrinology; 1992 Sep; 131(3):1188-94. PubMed ID: 1324153
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
Gespach C; Bawab W; de Cremoux P; Calvo F
Cancer Res; 1988 Sep; 48(18):5079-83. PubMed ID: 2842044
[TBL] [Abstract][Full Text] [Related]
10. Functional receptors for vasoactive intestinal peptide on human osteosarcoma cells.
Hohmann EL; Tashjian AH
Endocrinology; 1984 Apr; 114(4):1321-7. PubMed ID: 6323142
[TBL] [Abstract][Full Text] [Related]
11. Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.
Couvineau A; Rousset M; Laburthe M
Biochem J; 1985 Oct; 231(1):139-43. PubMed ID: 2998337
[TBL] [Abstract][Full Text] [Related]
12. Interaction of vasoactive intestinal peptide with a cell line (HeLa) derived from human carcinoma of the cervix: binding to specific sites and stimulation of adenylate cyclase.
Prieto JC; Guerrero JM; de Miguel C; Goberna R
Mol Cell Biochem; 1981 Jul; 37(3):167-76. PubMed ID: 6268963
[TBL] [Abstract][Full Text] [Related]
13. Cycle of the vasoactive intestinal peptide and its binding site in a human adenocarcinoma cell line (HT 29).
Luis J; Muller JM; Abadie B; Martin JM; Marvaldi J; Pichon J
Eur J Biochem; 1986 May; 156(3):631-6. PubMed ID: 3009188
[TBL] [Abstract][Full Text] [Related]
14. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
[TBL] [Abstract][Full Text] [Related]
15. Receptor-mediated actions of growth hormone releasing factor on granulosa cell differentiation.
Moretti C; Bagnato A; Solan N; Frajese G; Catt KJ
Endocrinology; 1990 Nov; 127(5):2117-26. PubMed ID: 2171907
[TBL] [Abstract][Full Text] [Related]
16. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture.
Boissard C; Marie JC; Hejblum G; Gespach C; Rosselin G
Cancer Res; 1986 Sep; 46(9):4406-13. PubMed ID: 3015387
[TBL] [Abstract][Full Text] [Related]
18. A receptor for VIP-related peptides with an unusual selectivity profile on the melanoma cell line IGR37.
Fabre C; Bellan C; Marvaldi J; Luis J
Melanoma Res; 1994 Dec; 4(6):379-83. PubMed ID: 7703717
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone-releasing hormone is produced by rat Leydig cell in culture and acts as a positive regulator of Leydig cell function.
Ciampani T; Fabbri A; Isidori A; Dufau ML
Endocrinology; 1992 Dec; 131(6):2785-92. PubMed ID: 1332849
[TBL] [Abstract][Full Text] [Related]
20. HT 29, a model cell line: stimulation by the vasoactive intestinal peptide (VIP); VIP receptor structure and metabolism.
Marchis-Mouren G; Martin JM; Luis J; el Battari A; Muller JM; Marvaldi J; Pichon J
Biochimie; 1988 May; 70(5):663-71. PubMed ID: 2844304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
